Functional genomics applications and therapeutic implications in sarcopenia.
Epigenomics
Functional genomics
Genomics
Metabolomics
Proteomics
RNA silencing
Sarcopenia
Trangenic mice
Journal
Mutation research. Reviews in mutation research
ISSN: 1388-2139
Titre abrégé: Mutat Res Rev Mutat Res
Pays: Netherlands
ID NLM: 101632211
Informations de publication
Date de publication:
Historique:
received:
31
07
2018
revised:
14
03
2019
accepted:
17
04
2019
entrez:
17
8
2019
pubmed:
17
8
2019
medline:
3
3
2020
Statut:
ppublish
Résumé
The human genome contains around 20,000-25,000 genes coding for 30,000 proteins. Some proteins and genes represent therapeutic targets for human diseases. RNA and protein expression profiling tools allow the study of the molecular basis of aging and drug discovery validation. Throughout the life, there is an age-related and disease-related muscle decline. Sarcopenia is defined as a loss of muscle mass and a decrease in functional properties such as muscle strength and physical performance. Yet, there is still no consensus on the evaluation methods of sarcopenia prognosis. The main challenge of this complex biological phenomena is its multifactorial etiology. Thus, functional genomics methods attempt to shape the related scientific approaches via an innovative in-depth view on sarcopenia. Gene and drug high throughput screening combined with functional genomics allow the generation and the interpretation of a large amount of data related to sarcopenia and therapeutic progress. This review focuses on the application of selected functional genomics techniques such as RNA interference, RNA silencing, proteomics, transgenic mice, metabolomics, genomics, and epigenomics to better understand sarcopenia mechanisms.
Identifiants
pubmed: 31416575
pii: S1383-5742(18)30064-4
doi: 10.1016/j.mrrev.2019.04.003
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
175-185Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.